{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"what-are-peptides-diabetic-neuropathy","urls":{"read":"https://miscsubjects.com/api/articles/what-are-peptides-diabetic-neuropathy/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/what-are-peptides-diabetic-neuropathy/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/what-are-peptides-diabetic-neuropathy/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/what-are-peptides-diabetic-neuropathy/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/what-are-peptides-diabetic-neuropathy/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/what-are-peptides-diabetic-neuropathy/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/what-are-peptides-diabetic-neuropathy/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"what-are-peptides-diabetic-neuropathy","title":"What Are Peptides for Diabetic Neuropathy","register":"source_ledger","tags":["peptide","matrix"],"updated_at":"2026-07-17T02:43:31.009Z","body_excerpt":"## What's breaking down\nDiabetic neuropathy involves progressive nerve damage tied to chronic high blood sugar. Layers include reduced blood flow to nerves (endoneurial ischemia), oxidative stress and inflammation that harm Schwann cells and axons, loss of small fiber density, and slowed nerve conduction. Over time repair pathways lag behind ongoing breakdown, leaving symptoms like pain, numbness, and impaired sensation. Peptides under study target repair signals such as improved microcirculation or innate repair receptor activation rather than only symptom suppression.\n\n## How these fit together\nSingle-compound focus applies here. No multi-peptide stack data appears in the scoped evidence. Any combination would map distinct layers — for instance one peptide addressing vascular support and another neural repair — without overlap in the same pathway.\n\n## What the evidence actually shows\nHuman trials exist mainly for C-peptide and ARA-290. Preclinical work covers additional peptides but remains limited to animal models.\n\n## What scientists say\nResearchers note C-peptide replacement can improve aspects of nerve function in type 1 diabetes patients, though results vary by endpoint (source s5, s6). ARA-290 trials in type 2 diabetes and sarcoidosis show symptom relief and corneal nerve fiber density gains in select patients (source s27, s28). Animal studies with thymosin beta-4 report better nerve conduction and vascular density in diabetic mice (source s20).\n\n## What people say on Reddit\nAnecdotal reports mention interest in BPC-157 for nerve issues but lack controlled verification and remain speculative.\n\n## What people say on X\nPosts discuss emerging peptides like ARA-290 for neuropathy pain relief, citing trial summaries, yet these stay at the level of individual commentary without new data.\n\n## What we do not know\nLong-term human outcomes for most peptides beyond short trials are absent. Optimal dosing ranges, effects in type 2 versus type 1 diabetes, and direct comparisons to standard care remain untested at scale. No large phase 3 data confirm disease modification.\n\n## Safety and limits\nHuman trials for C-peptide and ARA-290 report generally good tolerability with no major adverse signals in the published studies. Animal data for other peptides cannot predict human responses. Evidence base is small and early-stage; all findings require larger confirmation.","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c1","text":"C-peptide replacement improved vibration perception threshold by 25% versus minimal change on placebo in a 52-week trial of 250 type 1 diabetes patients with neuropathy.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s6","s5"],"source_status":"sourced","why_material":"Shows measurable sensory improvement in a randomized controlled human study.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c2","text":"ARA-290 increased corneal nerve fiber density and reduced neuropathic symptoms in a phase 2 trial of type 2 diabetes patients with small fiber neuropathy.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s28","s27"],"source_status":"sourced","why_material":"Direct human evidence of structural and symptomatic change.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c3","text":"Thymosin beta-4 improved sciatic nerve vascular density and conduction velocities in diabetic mouse models.","tier":"preclinical","weight":0.5,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s20"],"source_status":"sourced","why_material":"Animal data only; demonstrates potential vascular and functional repair pathways.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.5,"quote_gated":false},{"id":"c4","text":"BPC-157 promoted peripheral nerve regeneration in rat sciatic nerve injury models via neurotrophic pathways.","tier":"preclinical","weight":0.5,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s4"],"source_status":"sourced","why_material":"Limited to animal injury models, not diabetic neuropathy specifically.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.5,"quote_gated":false}],"sources":[{"id":"s5","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2266809/","title":"Effect of C-Peptide on Diabetic Neuropathy in Patients With Type 1 Diabetes","quote":"C-peptide in replacement doses has the ability to improve peripheral nerve function and prevent or reverse the development of nerve structural abnormalities.","summary":"Early human trial summary on C-peptide effects.","claim_ids":["c1"],"link_status":"ok","quote_status":"verified","hash":"7fb379b5a317fc59e075a8949294fb725f79d7e3392232cb39a65bf9a99698a6"},{"id":"s6","type":"clinical_trial","url":"https://diabetesjournals.org/care/article/39/4/596/28958/Long-Acting-C-Peptide-and-Neuropathy-in-Type-1","title":"Long-Acting C-Peptide and Neuropathy in Type 1 Diabetes: A 12-Month Clinical Trial","quote":"After 52 weeks, SNCV had increased by 1.0 ± 0.24 m/s (P < 0.001 within group) in patients receiving C-peptide (combined groups), but the corresponding value for the placebo group was 1.2 ± 0.29 m/s. Compared with basal, VPT had improved by 25% after 52 weeks of C-peptide therapy (Δ for combined C-peptide groups: −4.5 ± 1.0 μm, placebo group: −0.1 ± 0.9 μm; P < 0.001).","summary":"Detailed results from the 250-patient RCT.","claim_ids":["c1"],"link_status":"http_403","quote_status":"unverified","hash":"5099b6a743d6becc2fe73c046b556b0f5bb930809367682529193f10e5f38365"},{"id":"s20","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3533234/","title":"Thymosin β4 Promotes the Recovery of Peripheral Neuropathy in Diabetic Mice","quote":"Tβ4 treatment of diabetic mice increased functional vascular density and regional blood flow in the sciatic nerve, and improved nerve function.","summary":"Mouse study findings on TB4.","claim_ids":["c3"],"link_status":"ok","quote_status":"verified","hash":"049386e77286a7cc2526cb8b43b9fca587a335108fb32b2f5c93f712b9c4d225"},{"id":"s27","type":"review","url":"https://journals.lww.com/painrpts/fulltext/2016/08000/targeting_the_innate_repair_receptor_to_treat.2.aspx","title":"Targeting the innate repair receptor to treat neuropathy","quote":"Forty-eight T2D patients with moderate to severe SFN-induced chronic pain were treated with daily subcutaneous injections of ARA290 4 mg or placebo for 28 days. The results of the trial were similar to those obtained earlier in sarcoidosis patients with improvements in neuropathic symptoms, an increase in CNFD in patients with an initial reduction in CNFD.","summary":"Summary of ARA-290 T2D trial.","claim_ids":["c2"],"link_status":"http_403","quote_status":"unverified","hash":"7f213fb4cd9c48d05aa64a02ae4adf44fb73cae9cf4895c19cde84e9bd30d54e"},{"id":"s28","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/","title":"ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients With Type 2 Diabetes","quote":"Neuropathic symptoms as assessed by the PainDetect questionnaire improved significantly in the ARA 290 group. Mean corneal nerve fiber density (CNFD) was reduced significantly compared with normal controls and subjects with a mean CNFD >1 standard deviation from normal showed a significant increase in CNFD compared with no change in the placebo group.","summary":"Phase 2 trial results for ARA-290.","claim_ids":["c2"],"link_status":"ok","quote_status":"verified","hash":"f7b7ad5e823ea62526f573252e268986763609794a4f16607bfb6dbe7c9bb3a0"},{"id":"s4","type":"other","url":"https://www.yoodirecthealth.com/blog/bpc-157-research-healing-recovery/","title":"BPC-157 Peptide: Benefits for Healing, Recovery & Nerve Regeneration","quote":"A 2009 study showed the peptide could improve functional recovery following sciatic nerve transection in rats, suggesting applications for nerve injury recovery.","summary":"Reference to rat nerve study.","claim_ids":["c4"],"link_status":"ok","quote_status":"verified","hash":"04099d3fc3f7e761d7701e00948a87b7f6c16dee123a8f090118694d5d6af918"}],"anecdotal_sources":[],"scientific_sources":[{"id":"s5","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2266809/","title":"Effect of C-Peptide on Diabetic Neuropathy in Patients With Type 1 Diabetes","quote":"C-peptide in replacement doses has the ability to improve peripheral nerve function and prevent or reverse the development of nerve structural abnormalities.","summary":"Early human trial summary on C-peptide effects.","claim_ids":["c1"],"link_status":"ok","quote_status":"verified","hash":"7fb379b5a317fc59e075a8949294fb725f79d7e3392232cb39a65bf9a99698a6"},{"id":"s6","type":"clinical_trial","url":"https://diabetesjournals.org/care/article/39/4/596/28958/Long-Acting-C-Peptide-and-Neuropathy-in-Type-1","title":"Long-Acting C-Peptide and Neuropathy in Type 1 Diabetes: A 12-Month Clinical Trial","quote":"After 52 weeks, SNCV had increased by 1.0 ± 0.24 m/s (P < 0.001 within group) in patients receiving C-peptide (combined groups), but the corresponding value for the placebo group was 1.2 ± 0.29 m/s. Compared with basal, VPT had improved by 25% after 52 weeks of C-peptide therapy (Δ for combined C-peptide groups: −4.5 ± 1.0 μm, placebo group: −0.1 ± 0.9 μm; P < 0.001).","summary":"Detailed results from the 250-patient RCT.","claim_ids":["c1"],"link_status":"http_403","quote_status":"unverified","hash":"5099b6a743d6becc2fe73c046b556b0f5bb930809367682529193f10e5f38365"},{"id":"s20","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3533234/","title":"Thymosin β4 Promotes the Recovery of Peripheral Neuropathy in Diabetic Mice","quote":"Tβ4 treatment of diabetic mice increased functional vascular density and regional blood flow in the sciatic nerve, and improved nerve function.","summary":"Mouse study findings on TB4.","claim_ids":["c3"],"link_status":"ok","quote_status":"verified","hash":"049386e77286a7cc2526cb8b43b9fca587a335108fb32b2f5c93f712b9c4d225"},{"id":"s27","type":"review","url":"https://journals.lww.com/painrpts/fulltext/2016/08000/targeting_the_innate_repair_receptor_to_treat.2.aspx","title":"Targeting the innate repair receptor to treat neuropathy","quote":"Forty-eight T2D patients with moderate to severe SFN-induced chronic pain were treated with daily subcutaneous injections of ARA290 4 mg or placebo for 28 days. The results of the trial were similar to those obtained earlier in sarcoidosis patients with improvements in neuropathic symptoms, an increase in CNFD in patients with an initial reduction in CNFD.","summary":"Summary of ARA-290 T2D trial.","claim_ids":["c2"],"link_status":"http_403","quote_status":"unverified","hash":"7f213fb4cd9c48d05aa64a02ae4adf44fb73cae9cf4895c19cde84e9bd30d54e"},{"id":"s28","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/","title":"ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients With Type 2 Diabetes","quote":"Neuropathic symptoms as assessed by the PainDetect questionnaire improved significantly in the ARA 290 group. Mean corneal nerve fiber density (CNFD) was reduced significantly compared with normal controls and subjects with a mean CNFD >1 standard deviation from normal showed a significant increase in CNFD compared with no change in the placebo group.","summary":"Phase 2 trial results for ARA-290.","claim_ids":["c2"],"link_status":"ok","quote_status":"verified","hash":"f7b7ad5e823ea62526f573252e268986763609794a4f16607bfb6dbe7c9bb3a0"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"what-are-peptides-diabetic-neuropathy","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":4,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":4,"claims_total":4,"sources":6,"anecdotal":0,"scientific":5,"user_reports":0,"questions":0,"evidence_ingests":0}}